https://www.selleckchem.com/pr....oducts/amenamevir.ht
De novo mutations in the APC gene are responsible for 20-30% of FAP cases. In the presence of the characteristic RPE lesions, it is important to send the patient for work up of FAP even in the absence of family history of FAP. The interest in the use of beta-hydroxy-beta-methylbutyrate (HM as an intervention to prevent and treat sarcopenia has increased over recent years. The purpose of this review is to explore recent evidence pertaining to the mechanism of action of HMB and how this may influence changes in lean mass and strength